Caris Life Sciences (NASDAQ:CAI) Bolsa

CAI International

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Caris Life Sciences Inc

CA IMMOBILIEN ANLAGEN AG by CA Immobilien Anlagen AG

CA Immobilien Anlagen AG

CALIFORNIA INTL BANK by California International Bank

California International Bank NA

Calamos ETF Trust Calamos Autocallable Income ETF

CHIA TAI INTL LTD ORD by Chia Tai Enterprises International Ltd.

Chia Tai Enterprises International Ltd

CaixaBank SA

General

BMBL

CORRECTION: Bumble Shares Are Trading Higher

<a href="https://www.globenewswire.com/Tracker?data=Op8f-CK5pOlv-NlsQ3_NpVUDnAksnDvaDpwv3PEa9EyIC_j2s5c6oXaU80N-XNH0f0-lIuY7dB9Hx-dN4kA7YymRnJ34-oBTvsUZrs1ha7Y=">FAST TRACK GROUP</a> (NASDAQ:<a href="https://www.benzinga.com/stock/FTRK#NASDAQ">FTRK</a>) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, today issued the following statement in response to recent misinformation circulating on social media platforms, including multiple posts on X (formerly Twitter), falsely claiming that the Company is undertaking a $37 million registered direct offering.
Fast Track is aware of recent posts on social media and denies any claims that it is conducting a $37 million registered direct offering as of June 25, 2025. These statements are false and without merit. As of June 25, 2025, the Company has not announced, filed for, or entered into any such offering. The Company urges the public to rely only on official Company communications made through appropriate Regulation Fair Disclosure channels, such as press releases and filings with the U.S. Securities and Exchange Commission (SEC), for the most accurate and up-to-date information.

News

Offerings

Management

FTRK

Fast Track Group Denies False Social Media Claims Of $37M Stock Offering; Says "These Statements Are False And Without Merit"

Cereal Giant General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) shares dipped in premarket trading Wednesday after the company posted mixed fourth-quarter results and <a href="https://www.benzinga.com/pressreleases/25/06/b46091246/general-mills-reports-fiscal-2025-fourth-quarter-and-full-year-results-and-provides-fiscal-2026-ou" target="_blank" rel="noreferrer noopener">issued a cautious full-year outlook</a>.
The global packaged food company registered quarterly adjusted earnings per share of 74 cents, beating the analyst consensus estimate of 71 cents. Quarterly sales of $4.56 billion (down 3% year over year) missed the Street view of $4.59 billion.
Organic net sales fell 3%, as expected, including a 2-point hit from unfavorable trade expense timing.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44939726/rfk-jr-will-phase-out-artificial-food-dyes-by-end-of-2026-what-it-means-for-pepsi-coca-cola-general-mills" rel="noreferrer noopener">RFK Jr. Will Phase Out Artificial Food Dyes By End Of 2026: What It Means For Pepsi, Coca-Cola, General Mills</a>
Quarterly net sales for General Mills&#8217; North America Retail segment were down 10% to $2.6 billion,&nbsp;North America Pet segment were up 12% to $675 million, North America Food service segment were down 2% to $579 million, and International segment were up 11% to $739 million.
Adjusted gross margin was down 220 basis points to 32.7% of net sales, driven primarily by higher input costs and unfavorable net price realization and mix.
Unfavorable trade expense timing was a 150-basis point headwind to adjusted gross margin in the quarter.
Adjusted operating profit of $622 million was down 22% in constant currency, driven by lower adjusted gross profit dollars. Adjusted operating profit margin was down 330 basis points to 13.7%.&nbsp;
&#8220;Our number one goal in fiscal 2026 is to restore volume-driven organic sales growth,&#8221; said General Mills Chairman and Chief Executive Officer Jeff Harmening.
&#8220;To do that, we&#8217;ll invest further in consumer value, product news, innovation, and brand building, guided by our remarkable experience framework and highlighted by Blue Buffalo&#8217;s national launch into fresh pet food coming later in calendar 2025.&#8221;
The company exited the quarter with cash and equivalents worth $363.9 million and inventories worth $1.91 billion.
General Mills launched a multi-year global transformation initiative under its Accelerate strategy to streamline operations and enhance agility through new tools, technologies, and operating models.
The initiative, along with other efficiency efforts, is expected to deliver $100 million in incremental cost savings in FY2026.
The company declared a quarterly dividend of 61 cents per share, payable August 1, 2025, to shareholders of record July 10, 2025. This represents a 2% increase from the previous quarterly rate.
General Mills expects its fiscal 2026 adjusted diluted EPS to decline 10%-15% in constant currency from the fiscal year 2025 base of $4.21. The company projects organic net sales to range between a 1% decline and a 1% increase.
&#8220;With a clear framework centered on remarkability and positive early returns from our fourth quarter investments, I&#8217;m confident our fiscal 2026 plans will put us on a path back to driving long-term growth in line with our shareholder return model,&#8221; the CEO added.
Price Action: GIS shares are trading lower by 3.74% to $51.40 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45980305/kraft-heinz-bans-artificial-colors-in-us-products-eyes-full-phaseout-by-2027" target="_blank" rel="noreferrer noopener">Kraft Heinz Bans Artificial Colors In US Products, Eyes Full Phaseout By 2027</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Guidance

Markets

Movers

Cereal Giant General Mills' Cautious Outlook Offers Little Crunch, Stock Falls

Canaccord Genuity analyst Jason Tilchen initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $330.

Price Target

Initiation

Analyst Ratings

FLUT

Canaccord Genuity Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $330

Strong Booking Momentum Expected to Continue Through the Second Half of the Year
LETHAM, Scotland, June 25, 2025 /PRNewswire/ --&nbsp;MDJM LTD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UOKA#NASDAQ">UOKA</a>) (the "Company" or "MDJM"), an integrated global culture-driven asset management company, today announced substantial operational growth at its cultural property, Robin Hill Hotel in Torquay, England. The strong performance reflects the Company's ongoing strategic initiatives to enhance guest experiences through immersive cultural programming and elevated dining offerings.
As of June 20, 2025, Robin Hill Hotel has received full-year bookings totaling 911 room nights, compared to 227 total room nights booked in all of 2024, representing a 301% increase. The average daily rate (ADR) has also improved significantly—from £135 to £162, reflecting a 20% increase in average pricing. The Company expects continued growth as the summer peak and holiday seasons approach.

UOKA

MDJM Reports 301% Surge In Full-Year Bookings As Of June 2025 Compared To Total Bookings In 2024

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is accelerating the adoption of the Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark, with a growing interest in Finland.
Spjotgard, founded in 2021 by a team with deep pharmaceutical expertise, has rapidly developed a strong regional footprint, positioning INBS' fingerprint drug testing technology as its flagship solution in response to rising demand for modern, dignified approaches to drug testing.

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Sees Accelerated Nordic Adoption Of Fingerprint Drug Testing Through Spjotgard Partnership

--Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days
--Despite broad utilization in the study, rapid genomic sequencing in non-critical care inpatients yielded a diagnostic rate over 42%, comparable to critical care settings
--Study supports broader adoption of rapid genomic testing in the non-critical care inpatient setting to improve pediatric patient outcomes and lower healthcare costs
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genedx.com&amp;esheet=54281931&amp;newsitemid=20250625305855&amp;lan=en-US&amp;anchor=GeneDx&amp;index=1&amp;md5=f8f6eb06d0a65b08d3cd94cc3f8b5e24">GeneDx</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children's supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for non-critical pediatric inpatients. The study assessed the impact of using rES/rGS as a first-tier test for children receiving genetic consults in non-critical care settings. The researchers examined diagnostic rates before and after a new policy allowing rES/rGS as a first-tier test was implemented. An analysis published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jpeds.com%2Farticle%2FS0022-3476%252825%252900240-9%2Ffulltext&amp;esheet=54281931&amp;newsitemid=20250625305855&amp;lan=en-US&amp;anchor=The+Journal+of+Pediatrics&amp;index=2&amp;md5=6f52548a072da7a293f550e48149366a">The Journal of Pediatrics</a> showed that rapid genome testing dropped the average time to a precise genetic diagnosis from almost ten months to less than two weeks.
"Pediatric inpatients often remain undiagnosed and stuck in limbo without answers or treatment as their conditions worsen and costs rise for way too long," said Mike Bamshad, MD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Division Chief of Genetic Medicine at Seattle Children's. "The study demonstrated how a policy change allowing for rapid genomic testing as a first-tier test significantly reduced the time to diagnosis in non-critical care pediatric wards, enabling patients to receive timely treatments and potential better outcomes."
Implementation of the SeqFirst approach in the clinical setting led to significant reductions in the time to a genetic diagnosis, with the average time dropping from 289 to 13 days following the policy change that enabled rES/rGS to be ordered as a first-tier test in non-critical care pediatric wards. Despite an increase in utilization of rES/rGS, the diagnostic yield remained high, exceeding 40 percent, comparable to rates in critical care settings. The acceleration of diagnoses enables earlier interventions, better care planning, and improved outcomes for children with rare and undiagnosed conditions.
"Access to rapid genomic testing shouldn't be limited by where a child is admitted in the hospital," said Tara Wenger, MD, PhD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Associate Medical Director, Inpatient Service at Seattle Children's. "This study shows that when we remove outdated barriers and bring cutting-edge diagnostics to the broader inpatient setting, we can deliver faster answers, reduce uncertainty for families, and ensure more children benefit from the highest standard of genomic care, regardless of their level of acuity."
Additional findings from the study:
<ul>
<li>Providers caring for patients in pediatric inpatient settings are good at recognizing which patients are appropriate candidates for genetic testing, with 91 percent of consults resulting in the geneticist recommending testing.</li>
<li>When rES/rGS is not used, cases may be lost to follow-up, which delays access to testing and therefore a diagnosis.</li>
<li>The rate at which a precise genetic diagnosis was made from the initial encounter was over 3 times higher when rES/rGS was implemented as a first line test.</li>
</ul>
"This study underscores a major opportunity to expand timely, precise genetic diagnoses in non-critical care inpatients, a setting where genomic testing remains underutilized," said Britt Johnson, PhD, FACMG, SVP of Medical Affairs at GeneDx. "As health systems aim to deliver care more efficiently, expanding rES/rGS access across pediatric inpatients should reduce costs, shorten hospital stays, minimize unnecessary procedures, and improve outcomes for patients and families."

Biotech

GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients In The Journal of Pediatrics. Rapid Genomic Sequencing In Non-Critical Care Inpatients Yielded A Diagnostic Rate Over 42%

Mega Matrix Purchases 12 Bitcoins As Part Of Treasury Strategy At Average Price Of ~$105,554 Per Bitcoin

WIIM

Bumble share are trading lower after the company announced it is reducing the size of its team.

The Tachyonext partnership marks Nocera's official entry into the fast-growing U.S. direct-to-consumer (DTC) e-commerce space
TAIPEI, TW / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 25, 2025 / Nocera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) ("Nocera" or the "Company"), an industry-agnostic, acquisition-focused company, today announced that it has entered into a definitive agreement regarding a strategic partnership through its $500,000 investment in Tachyonext Inc., a technology and supply chain solutions firm.
Nocera's strategic investment in Tachyonext Inc. allows the company to acquire a 35% equity stake as part of its broader diversification strategy into high-growth, tech-driven consumer sectors. This marks Nocera's official entry into the fast-growing U.S. direct-to-consumer (DTC) e-commerce space.

NCRA

Nocera Enters Into Definitive Agreement Regarding Strategic Partnership Through $500K Investment In Tachyonext

ALLT

Allot shares are trading lower after the company announced the pricing of its $40 million public offering of 5 million shares at $8.00 per shares.

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

CTSO

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

Galaxy Payroll Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>, "Galaxy Group"))), a leading global payroll provider, announced today the signing of a Memorandum of Understanding (MOU) to jointly develop innovative AI-powered HR solutions. The partnership will combine Galaxy's payroll expertise with CURRENC's artificial intelligence technology to create advanced tools for modern workforce management. The cooperation, as outlined in the MOU, will focus on the development of two key modules that leverage the combined strengths of both parties. The "AI HR &amp; Payroll Manager" will integrate Galaxy's extensive payroll expertise with CURRENC's advanced AI capabilities to streamline and enhance HR and payroll operations. This module will also introduce cryptocurrencies, particularly stablecoins, as a payment option for payroll processing, aligning with the growing trend of digital payments and offering clients a more efficient and secure payment alternative.

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

GLXG

Galaxy Group Signs MOU With CURRENC To Jointly Develop Innovative AI-Powered HR Solutions

CURV

Torrid Holdings shares are trading lower after the company announced the pricing of a secondary offering of 10 million shares at $3.50 per share.

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1.png" alt="" class="wp-image-14853" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The cosmetic surgery specialist's shares have nearly doubled in the last two weeks as investors flock to its new business model centered on self-operated clinics
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>So-Young has delayed implementation of a planned reverse share split following a surge that has seen its stock price nearly double in the last two weeks</li>
<li>The cosmetic surgery specialist is shifting its business model from referring people to third-party clinics to operating its own facilities to give it better quality control</li>
</ul>
Cosmetic surgery specialist So-Young International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) appears to be having second thoughts about its latest plan involving a makeover for its stock, which was ailing as recently as May 30 when it announced the equivalent of a 19.5-to-1 reverse share split. Such reverse splits are used by U.S.-listed companies to bring their prices back above the $1 level as required by New York Stock Exchange and Nasdaq listing rules.
So-Young's stock fell below the $1 mark on an extended basis last June, prompting the Nasdaq to notify it of failure to comply with listing requirements. Its reverse share split would have brought it back into compliance by raising its price well above the $1 mark, and was set to take effect on June 30.
But then the company's shares suddenly began to surge about two weeks ago, taking them above the $1 mark on June 17. They've continued to climb since then, and, at Tuesday's close of $1.71, have nearly doubled over the last two weeks. That sudden surge was most likely what prompted the company to&nbsp;<a href="https://www.prnewswire.com/news-releases/so-young-announces-extension-of-plan-to-implement-ads-ratio-change-302486910.html">announce</a>&nbsp;last Friday it was reconsidering its reverse share split decision. It said it needed "additional time to finalize preparations" for the move and would announce a new date in the future.
So, what's happening here?
While it's possible the recent rally is coming from speculators looking to make some quick money, a more likely reason is that investors are just now discovering So-Young's own internal makeover that has the potential to return it to strong growth. Even after the rally, So-Young's stock still trades at a relatively low price-to-sales (P/S) ratio of 0.85. That's still ahead of Chinese hair transplant specialist&nbsp;Yonghe Medical's&nbsp;0.32, but behind a more typical 1.73 for&nbsp;Perfect Medical&nbsp;(1830.HK), which operates centers in the more mature Hong Kong market.
Put simply, So-Young is discovering the importance of quality control, especially for something as sensitive as cosmetic surgery, where a few inexperienced doctors and shoddy surgeries can quickly spoil a company's reputation. In the past, So-Young was mostly an intermediary, helping to link consumers with the thousands of cosmetic surgery centers across China, and taking referral fees as its main revenue sources.
But that business proved problematic due to the difficulty of controlling quality among the many clinics on So-Young's network. Making matters worse for its core client base, health regulators in 2023 began requiring operators of all such centers to get licensed before being allowed to advertise their services. At that time, only about 13,000 such clinics were licensed, and a much larger 80,000 lacked any official qualifications, according to independent research.
Realizing the difficulty of operating in such an environment, So-Young made the decision about two years ago to start operating its own clinics where it could have complete control over the quality of not only its products, but also its personnel and service levels. That part of its business has developed quickly and looks likely to become its main revenue source in the next year or two.
"We believe the big key to our next phase hinges on developing our aesthetic center business with full control over the supply chain," said Chairman Jin Xing on the company's latest earnings call last month.
<h4 class="wp-block-heading">Rocky road</h4>
So-Young has traveled a rocky road since its New York IPO in May 2019, when it raised $180 million by selling shares for $13.80 apiece. The pandemic began less than a year later, putting huge pressure on its business as people put off cosmetic surgery for fear of being infected by Covid-19. As a result, the company's revenue went into reverse in 2022, falling 26% that year, before rebounding somewhat with the pandemic's end in 2023.
But even after the pandemic's end, the company was hit by the regulatory crackdown, causing its revenue to contract again by a milder 2% last year. The contraction hasn't ended yet, and So-Young's&nbsp;<a href="https://www.prnewswire.com/news-releases/so-young-reports-unaudited-first-quarter-2025-financial-results-302457679.html">latest results</a>&nbsp;show its revenue fell 6.7% in this year's first quarter to 297 million yuan ($41 million) from 318 million yuan a year earlier.
That drop was due to a 34% decline in the company's "information and reservations" services, which include the referral fees it receives from directing customers to clinics. That part of its business generated 143 million yuan in the first quarter, or just under half of its revenue for the period. By comparison, that part of the business brought in 217 million yuan a year earlier, when it accounted for more than two-thirds of the company's revenue.
While that part of its business was fading, the company's newer aesthetic treatment services from its growing chain of self-operated clinics was rapidly growing. Revenue from that part of the business jumped more than sixfold in the first quarter to 98.8 million yuan, making up one-third of its total, from just 15.2 million yuan a year earlier, when it accounted for just 5%.
The company said it expects that part of the business to keep growing rapidly as it opens new clinics, forecasting revenue from that segment of between 120 million yuan and 140 million in the second quarter. The company currently operates 23 aesthetic centers in major cities across China, among which only four have been open more than a year. It said on its earnings call it expects to open around 13 new clinics annually over the next few years.
"Our branded aesthetic centers continue to generate strong growth momentum, achieving triple-digit year-over-year revenue growth," said Jin. "We are confident this momentum will continue as we scale, enabling us to address key customer pain points and elevate the overall medical aesthetic experience."
We would tend to agree that So-Young's new business model looks better positioned for success, though it remains to be seen whether China's slowing economy and growing consumer caution might dampen demand for cosmetic surgery in general. But one thing that's more certain is that interest seems to be returning to the company's stock. As a result, we wouldn't be surprised to see So-Young ultimately cancel its previously announced reverse share split plan.

Global

Opinion

Signals

Trading Ideas

So-Young Shares Get A Makeover

QuantumScape shares are trading higher after the company achieved a key 2025 milestone by successfully integrating its advanced Cobra separator process into baseline cell production.

Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing what it believes to be first-in-class therapies to treat mitochondrial diseases and combat age-related decline, and Launch One Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPAA#NASDAQ">LPAA</a>, "Launch One"))), a special purpose acquisition company focused on healthcare innovation, announce entering into a definitive business combination agreement (the "Business Combination Agreement").&nbsp; &nbsp;
Transaction highlights:
<ul>
<li>The proposed business combination (the "Business Combination") will create a publicly traded, clinical-stage biotechnology company focused on developing and commercializing Mitochondrial Augmentation Technology (MAT) – a proprietary platform designed to address a broad spectrum of diseases driven by mitochondrial dysfunction, from rare pediatric disorders to common adult conditions.</li>
<li>Upon closing of the transaction, the combined entity will operate under the name Mito US One Ltd. and is expected to be listed on Nasdaq.</li>
<li>The transaction is expected to provide Minovia with additional capital to facilitate accelerating its growth and development pipeline. This includes potentially reaching clinical and regulatory milestones, technology transfer, and the eventual commercial launch of the Company's longevity-focused offerings from its MAT platform.</li>
<li>The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and shareholder approvals.</li>
<li>Launch One's trust account currently holds approximately $239.7 million in cash, a portion of which may be available to the combined company following the transaction, depending on the extent of redemptions by public shareholders. &nbsp;</li>
</ul>

LPAA

Minovia Therapeutics To Go Public Via Merger With Launch One Acquisition Corp., Forming Mito US One Ltd. To Advance Mitochondrial Therapies

AVAV

AeroVironment shares are trading higher after the company reported better-than-expected Q4 financial results.

Synchronoss Technologies, Inc. ("Synchronoss") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>), a global leader and innovator in personal cloud platforms for telecoms, today announced that it has achieved certification under the EU-U.S. Data Privacy Framework (DPF), administered by the U.S. Department of Commerce.
The DPF is a transatlantic data transfer mechanism that enables U.S.-based organizations to receive and process personal data from the European Union in compliance with European privacy laws, such as the General Data Protection Regulation (GDPR). The framework provides robust safeguards, enforcement mechanisms, and redress options to ensure personal data remains protected when transferred outside the EU.
The DPF certification reinforces Synchronoss's longstanding commitment to international privacy standards and strengthens its position as a trusted partner to Tier 1 telecom operators around the world.

Comments

Caris Life Sciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL